Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Results of a Phase 1, Dose-Escalation Study of FF-10501-01 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Hypomethylating Agent (HMA)-Resistant Myelodysplastic Syndrome (MDS)

Guillermo Garcia-Manero, MD, Michael R. Kurman, MD, Courtney D. DiNardo, MD MSc, Naveen Pemmaraju, MD, Yesid Alvarado, MD, Kiran Naqvi, MD MPH, Farhad Ravandi, MD, Elias J. Jabbour, MD, Ricardo Delumpa, BSN, Timothy Madden, PhD, Gary Maier, PhD, Hiroyuki Iwamura, PhD, Hagop M. Kantarjian, MD

Blood (2018) 132 (Supplement 1): 1438.

https://doi.org/10.1182/blood-2018-99-116613

Published: 2018

Journal Articles

Anti-Leukemia Effect of FF-10501-01, a Novel Inosine 5'-Monophosphate Dehydrogenase Inhibitor, in Advanced Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS), Including Hypomethylating Agent (HMA) Failures

Guillermo Garcia-Manero, MD, Hui Yang, MD PhD, Zhihong Fang, Courtney DiNardo, MD, Elias Jabbour, MD, Naveen Pemmaraju, MD, Ricardo Delumpa, RN, Christopher Loiselle, RN, Susan Denton, RN, Whitney Smith, Hiroyuki Iwamura, PhD, Teletha Gipson, PhD, Michele Rosner, MS, Timothy Madden, PharmD, Thomas J. Myers, MD, Linda J. Paradiso, DVM, MBA

Blood (2015) 126 (23): 3800.

https://doi.org/10.1182/blood.V126.23.3800.3800

Published: 2015

Journal Articles

Pharmacokinetic Dose Guidance of IV Busulfan with Fludarabine with Allogeneic Stem Cell Transplantation Improves Progression Free Survival in Patients with AML and MDS; Results of a Randomized Phase III Study

Borje S Andersson, MD, PhD, Marcos J de Lima, MD, Rima M Saliba, PhD, Elizabeth J Shpall, MD, Uday Popat, M.D., Roy Jones, MD, PhD, Yago Nieto, MD, PhD, Chitra M Hosing, MD, Partow Kebriaei, MD, Amin M Alousi, MD, Laura L. Worth, MD, PhD, Timothy Madden, Pharm.D., Alison Gulbis, Pharm.D., Julianne J Chen, Gabriela Rondon, MD, Patricia McAdams, RN, Becky McMullin, RN, Michael Andreeff, M.D., Ph.D., Richard Champlin, MD

Blood (2011) 118 (21): 892.

https://doi.org/10.1182/blood.V118.21.892.892

Published: 2011

Journal Articles

Intravenous Busulfan Plus Melphalan Is a Highly Effective, Non-Toxic Preparative Regimen for Autologous Stem Cell Transplantation (ASCT) in Patients with Advanced Lymphoid Malignancies.

Partow Kebriaei, MD, Timothy Madden, BS, PHARMD, Reza Kazerooni, RPH, Elizabeth Shpall, MD, Xuemei Wang, MS, Peter Thall, MD, Chitra Hosing, MD, Muzaffar Qazilbash, MD, Uday Popat, MD, Celina Ledesma, BS, Issa Khouri, MD, Richard Champlin, MD, Roy Jones, MD, Borje S. Andersson, MD

Blood (2009) 114 (22): 3415.

https://doi.org/10.1182/blood.V114.22.3415.3415

Published: 2009

Journal Articles

Clofarabine (Clo) +/− Fludarabine (Flu) with IV Busulfan (Bu) and Allogeneic Stem Cell Transplantation (Allo-SCT) for Relapsed, Refractory Myeloid Leukemia (ML) and MDS

Borje S. Andersson, MD, PhD, Marcos de Lima, MD, Laura L. Worth, MD, PhD, Uday Popat, MD, Roy B. Jones, MD, PhD, Elizabeth J. Shpall, MD, Chitra Hosing, MD, Timothy Madden, BS, PHARMD, Reza Kazerooni, RPH, Patricia McAdams, BSN, Amin Alousi, MD, Partow Kebriaei, MD, Richard E. Champlin, MD

Blood (2008) 112 (11): 4390.

https://doi.org/10.1182/blood.V112.11.4390.4390

Published: 2008

Journal Articles

Intravenous (i.v.) Busulfan (Bu) Plus Melphalan (Mel) Is a Well-Tolerated Preparative Regimen for Stem Cell Transplantation (SCT) in Patients (pts) with Advanced Lymphoid Malignancies.

Partow Kebriaei, MD, Timothy Madden, PhD, Neil Thapar, PharmD, Elizabeth J. Shpall, MD, Chitra Hosing, MD, Muzaffar H. Qazilbash, MD, Marcos de Lima, MD, Peter F. Thall, PhD, Stacie Wright, Issa F. Khouri, MD, Richard E. Champlin, MD, Roy Jones, MD, PhD, Borje S. Andersson, MD, PhD

Blood (2005) 106 (11): 2742.

https://doi.org/10.1182/blood.V106.11.2742.2742

Published: 2005

Journal Articles

Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS

Marcos de Lima, Daniel Couriel, Peter F. Thall, Xuemei Wang, Timothy Madden, Roy Jones, Elizabeth J. Shpall, Munir Shahjahan, Betty Pierre, Sergio Giralt, Martin Korbling, James A. Russell, Richard E. Champlin, Borje S. Andersson

Blood (2004) 104 (3): 857–864.

https://doi.org/10.1182/blood-2004-02-0414

Published: 2004

NARROW

Results of a Phase 1, Dose-Escalation Study of FF-10501-01 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Hypomethylating Agent (HMA)-Resistant Myelodysplastic Syndrome (MDS)

Anti-Leukemia Effect of FF-10501-01, a Novel Inosine 5'-Monophosphate Dehydrogenase Inhibitor, in Advanced Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS), Including Hypomethylating Agent (HMA) Failures

Pharmacokinetic Dose Guidance of IV Busulfan with Fludarabine with Allogeneic Stem Cell Transplantation Improves Progression Free Survival in Patients with AML and MDS; Results of a Randomized Phase III Study

Intravenous Busulfan Plus Melphalan Is a Highly Effective, Non-Toxic Preparative Regimen for Autologous Stem Cell Transplantation (ASCT) in Patients with Advanced Lymphoid Malignancies.

Clofarabine (Clo) +/− Fludarabine (Flu) with IV Busulfan (Bu) and Allogeneic Stem Cell Transplantation (Allo-SCT) for Relapsed, Refractory Myeloid Leukemia (ML) and MDS

Intravenous (i.v.) Busulfan (Bu) Plus Melphalan (Mel) Is a Well-Tolerated Preparative Regimen for Stem Cell Transplantation (SCT) in Patients (pts) with Advanced Lymphoid Malignancies.

Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS

Email alerts

ASH Publications

American Society of Hematology

Results of a Phase 1, Dose-Escalation Study of FF-10501-01 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Hypomethylating Agent (HMA)-Resistant Myelodysplastic Syndrome (MDS)

Anti-Leukemia Effect of FF-10501-01, a Novel Inosine 5'-Monophosphate Dehydrogenase Inhibitor, in Advanced Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS), Including Hypomethylating Agent (HMA) Failures

Pharmacokinetic Dose Guidance of IV Busulfan with Fludarabine with Allogeneic Stem Cell Transplantation Improves Progression Free Survival in Patients with AML and MDS; Results of a Randomized Phase III Study

Intravenous Busulfan Plus Melphalan Is a Highly Effective, Non-Toxic Preparative Regimen for Autologous Stem Cell Transplantation (ASCT) in Patients with Advanced Lymphoid Malignancies.

Clofarabine (Clo) +/− Fludarabine (Flu) with IV Busulfan (Bu) and Allogeneic Stem Cell Transplantation (Allo-SCT) for Relapsed, Refractory Myeloid Leukemia (ML) and MDS

Intravenous (i.v.) Busulfan (Bu) Plus Melphalan (Mel) Is a Well-Tolerated Preparative Regimen for Stem Cell Transplantation (SCT) in Patients (pts) with Advanced Lymphoid Malignancies.

Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only